Over his fifty-year tenure at the Johns Hopkins School of Medicine, Dr. Griffiths dedicated years to investigating the effects of mood-altering substances, including opiates, cocaine, sedatives, alcohol, nicotine, and caffeine, on the human brain.
In 1999, Johns Hopkins University gave Dr. Griffiths the green light to resume research into the medical promise of psilocybin – a decision that catapulted the psychedelic medicines field.
Read our coverage here.
Patients in some of the most deprived areas of England, where respiratory conditions including chronic lung disease (COPD) and asthma are most prevalent, have limited
A new editorial paper was published in Oncoscience (Volume 10) on August 17, 2023, entitled, “Cancer drug development yesterday, today and tomorrow.”
Wound Company Executive Team What You Should Know: Making a Change with Evidence-Based Wound-Care The US is experiencing an amputation epidemic due to diabetic foot